Clinical Trial: Phase Ia Study of MST-931 in Healthy Adult Subjects

U.S., Oct. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07903493) titled 'Phase Ia Study of MST-931 in Healthy Adult Subjects' on Oct. 18.

Brief Summary: A Phase 1a, randomized, double-blind study of MST-931 in healthy participants.

The purpose of this research is to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a single subcutaneous dose of MST-931 given to healthy participants. MST-931 is a monoclonal antibody.

Study Start Date: Nov. 30

Study Type: INTERVENTIONAL

Condition: Ankylosing Spondylitis (AS)

Intervention: BIOLOGICAL: MST-931

MST-931 is a proprietary monoclonal antibody developed by Mabsoft Therapeutics.

BIOLOGICAL: MST-931 Placebo

Mat...